

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 15, 2022**

**Caribou Biosciences, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-40631**  
(Commission File Number)

**45-3728228**  
(IRS Employer  
Identification No.)

**2929 7th Street, Suite 105**  
**Berkeley, California**  
(Address of Principal Executive Offices)

**94710**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (510) 982-6030**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.0001 par value per share	CRBU	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Matters.**

On July 15, 2022, Caribou Biosciences, Inc. (the “Company”) announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) is scheduled to be held at 7:30 a.m. PDT on Tuesday, September 20, 2022. The record date for the 2022 Annual Meeting will be August 4, 2022. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2022 Annual Meeting, or any adjournment or postponement thereof. The 2022 Annual Meeting will be a virtual meeting, conducted as a live webcast. Further details regarding the 2022 Annual Meeting will be provided at a later date.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CARIBOU BIOSCIENCES, INC.**

Date: July 15, 2022

By: /s/ Rachel E. Haurwitz

**Rachel E. Haurwitz**  
**President & Chief Executive Officer**

---

